Intrinsiqs

Is Immunovant, Inc. overvalued?

Immunovant, Inc. (IMVT) — key valuation metrics and fundamentals.

No verdict
Price
$41.82
Fair value
Current P/E
Normal P/E
Market cap
$8.63B
Dividend yield
0.0%
Return on equity
-69.6%
Sector
Healthcare

See the full interactive analysis →

Fair value compares IMVT's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.